The Cuban vaccine against the Abdala coronavirus during the third phase of clinical trials has shown 100% effectiveness against severe forms of the disease and death. It is reported by TASS with reference to local media.
Martha Ayala, director of the National Center for Genetic Engineering and Biotechnology, said that now the focus group for the study of the effectiveness of the vaccine is planned to be increased to 300 thousand people.
The Cuban medical authorities have previously issued an emergency authorization for the Abdala vaccine. This happened after it was announced that the drug was 92.28 percent effective against the symptomatic course of the coronavirus.
Abdala is a three-component drug. The vaccination schedule assumes injections 14 and 28 days after the first vaccination.
Also in Cuba, the Soberana 02 vaccine was developed. The effectiveness of two doses of this drug was 62 percent, which exceeds the 50 percent threshold set by the World Health Organization (WHO) for candidate vaccines against COVID-19.
More than 4.3 million people have participated in the trials of Cuban vaccines.